Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence

Simple item page
dc.contributor.affiliationEli Lilly Australia Pty Ltd, 112 Wharf Rd, W Ryde, NSW 2114, Australiaes_ES
dc.contributor.emailkelin_katarina@lilly.comes_ES
dc.creatorKelin, Katarina
dc.creatorBrnabic, Alan J.M.
dc.creatorNewton, Richard
dc.creatorEscamilla, Raúl I.
dc.creatorChuo, Liang-Jen
dc.creatorSimu, Malina
dc.creatorYe, Wenyu
dc.creatorMontgomery, William
dc.creatorKaragianis, Jamie
dc.creatorAscher-Svanum, Haya
dc.creator.identificador"EAOR750420HNLSRL08">Escamilla Orozco, Raúl Ivánes_ES
dc.date.accessioned2017-06-30T03:51:56Z
dc.date.accessioned2026-03-27T14:51:58Z
dc.date.available2017-06-30T03:51:56Z
dc.date.issued2010es_ES
dc.date.published2010es_ES
dc.description.abstractotrodiomaIn this year-long, prospective observational study, sociodemographic, clinical, and functional characteristics were assessed in outpatients with schizophrenia from Australia, Mexico, Romania, and Taiwan who were switched from their primary oral antipsychotic to another oral or depot antipsychotic at study entry because of physician-perceived nonadherence risks. Patients (N = 406) rated their quality of life and functioning level as low. Few patients (10.6%, 43/406) were switched to depot antipsychotics, with country-specific differences (P < 0.001). Although illness severity was similar between subgroups, the depot switch subgroup had: a documented history of nonadherence (32.6% versus oral: 4.7%)| recent alcohol (48.8% versus 23.2%| P < 0.001) or illicit drug use (16.3% versus 5.0%| P = 0.010)| recent depot antipsychotic (20.7% versus 7.5%| P = 0.030) and mood stabilizer use (51.7% versus 26.3%| P = 0.008)| poorer attitudes towards medication (P = 0.004)| and poorer illness awareness (P = 0.041). Findings indicate that even when a risk of nonadherence has been identified, few patients with schizophrenia receive depot antipsychotics, despite being prime candidates for depot therapy. Findings suggest physicians may select depot therapy based on previous nonadherence, substance use, recent depot antipsychotic and mood stabilizer use, poor attitudes towards medications, and poor illness awareness.es_ES
dc.identifier2336es_ES
dc.identifier.citationTomás Martínez Ibarraes_ES
dc.identifier.eissn1177-889Xes_ES
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñizes_ES
dc.identifier.paginacion301-311es_ES
dc.identifier.placeNew Zealandes_ES
dc.identifier.urihttps://doi.org/10.2147/PPA.S11934es_ES
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943222/es_ES
dc.identifier.urihttps://repositorio.inprf.gob.mx/handle/123456789/6981
dc.identifier.volumen4es_ES
dc.language.isoenges_ES
dc.publisherDOVE MEDICAL PRESS LTD, PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALANDes_ES
dc.relation4, 301-311 p.es_ES
dc.relationversión del editores_ES
dc.relation.jnabreviadoPATIENT PREFER ADHERENCEes_ES
dc.relation.journalPatient Preference and Adherencees_ES
dc.rightsacceso cerradoes_ES
dc.subject.koAntipsychotic drugses_ES
dc.subject.koSchizophreniaes_ES
dc.subject.koDepot antipsychotices_ES
dc.subject.koNonadherencees_ES
dc.subject.kwFármacos antipsicóticoses_ES
dc.subject.kwEsquizofreniaes_ES
dc.subject.kwDepósito de antipsicóticoses_ES
dc.subject.kwFalta de adherenciaes_ES
dc.titleBaseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherencees_ES
dc.typearticlees_ES

Files

Collections

Artículos de revista